Kensey Nash announces strategic agreement with Arthrex for ECM technology

Kensey Nash Corporation (Nasdaq: KNSY), a regenerative medicine company, and Arthrex, Inc., a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons, today announced a strategic agreement regarding products developed from Kensey Nash's unique extracellular matrix (ECM) technology.

The agreement is based upon Kensey Nash's proprietary tissue processing technology, known as the Optrix™ process, which gently disinfects tissues, inactivates viruses and removes cells while preserving extracellular matrix components.  Under the agreement, Kensey Nash will develop and manufacture porcine dermis derived biologic surgical meshes, which Arthrex will market and distribute for use in sports medicine tendon repair procedures and small joint surgeries. ECM products can be used in a wide variety of surgical procedures, including sports medicine, for the reinforcement and repair of soft tissue.  Specific terms of the agreement were not disclosed.

"This partnership represents another important milestone as we continue to establish Kensey Nash's leadership position as a developer of innovative regenerative medicine devices," commented Joseph W. Kaufmann, President and CEO of Kensey Nash. "Arthrex is a highly respected global leader in the sports medicine industry and we look forward to building upon our successful history together with this exciting new product line," he concluded.

Source:

Kensey Nash Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology